Bio­gen pulls PRIME des­ig­na­tion for ad­u­canum­ab in Eu­rope; Mer­ck clos­es merg­er with Ac­celeron

Fol­low­ing news last week that Bio­gen re­ceived “a neg­a­tive trend vote” in Eu­rope for its con­tro­ver­sial Alzheimer’s drug ad­u­canum­ab, the EMA up­dat­ed a list of PRIME des­ig­na­tions in­di­cat­ing that some, in­clud­ing Bio­gen, pulled out of the EU’s pri­or­i­ty med­i­cines scheme, known as PRIME.

But Bio­gen said in a state­ment to End­points News that it ac­tu­al­ly pulled the PRIME des­ig­na­tion for ad­u­canum­ab in 2019, not­ing that it oc­curred “fol­low­ing the dis­con­tin­u­a­tion of the EMERGE and EN­GAGE stud­ies,” and that it “was a pro­ce­dur­al re­quire­ment at the time.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER